Rallybio Corp (NASDAQ: RLYB)

Rallybio Corp, a clinical-stage biotechnology company, is dedicated to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. The company operates in the biotechnology industry, focusing on the development of novel therapeutics for rare diseases. Specifically, Rallybio's main business activities involve the development of therapies for maternal-fetal blood disorders, complement dysregulation, hematology, and metabolic disorders. The company operates primarily in the United States, with its headquarters located in Connecticut.

Rallybio generates revenue through the development and commercialization of its novel therapeutics. The company's primary products include RLYB211 and RLYB212, which are being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). RLYB211 is an intravenously administered polyclonal anti-human platelet antigen-1a (HPA-1a) antibody, while RLYB212 is a subcutaneously administered human monoclonal anti-HPA-1a antibody. Both of these products have shown promising results in clinical trials, demonstrating their ability to rapidly and completely eliminate HPA-1a-positive platelets from the circulation of HPA-1a-negative subjects (Rallybio Corp, 2